Drug Profile
DV 1001
Alternative Names: DV1001; TLR 7 and 8 agonist - DynavaxLatest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator Dynavax Technologies
- Class Antineoplastics
- Mechanism of Action Immunostimulants; Toll-like receptor 7 agonists; Toll-like receptor 8 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for preclinical development in Cancer in USA
- 13 Mar 2017 Preclinical trials in Cancer in USA before March 2017 (Dynavax Technologies form 10-K, filed in March 2017)